이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects

2018년 4월 26일 업데이트: GlaxoSmithKline

Booster Vaccination Study to Assess Safety & Reactogenicity of a Dose of DTPw-HBV/Hib Vaccine and to Assess the Immunogenicity, Safety & Reactogenicity of a Dose of Mencevax™ ACW in Subjects Primed in Study 759346/007

The purpose of this study is to assess the safety and reactogenicity of a booster dose of diphtheria-tetanus-whole cell pertussis-hepatitis B virus/Haemophilus influenzae type b vaccine (DTPw-HBV/Hib) at 15-18 m and to assess the immunogenicity, safety, and reactogenicity of a dose of Mencevax™ Group A, C and W135 polysaccharide meningococcal vaccine (ACW) at 24 to 30 m in primed subjects.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

This open study will have two parallel groups based on the vaccination received in the primary study: AC primed Group: primed with Tritanrix™-HepB/Hib-MenAC vaccine and AC unprimed Group (control): primed with Tritanrix™-HepB/Hiberix™ vaccine. All subjects will receive a booster dose of Tritanrix™-HepB/Hiberix™ vaccine at 15 to 18 months of age with GSK Biological's OPV vaccine given concomitantly and a dose of Mencevax™ ACW vaccine at 24 to 30 months of age. Blood sampling will be done prior to (pre) and one month after (post) the Mencevax™ ACW vaccine administration for immunogenicity analyses. The study will last minimum 7 to maximum 16 months per subject.

Mencevax™ ACWY was changed to Mencevax™ ACW throughout the posting to correct an inconsistency in the earlier version of the protocol posting and to reflect the actual situation.

연구 유형

중재적

등록 (실제)

168

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

  • 남아프리카
      • Brits, 남아프리카, 0250
        • GSK Investigational Site
      • Ga-Rankuwa, 남아프리카, 0208
        • GSK Investigational Site
      • Rooihuiskraal, 남아프리카, 0145
        • GSK Investigational Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

1년 (어린이)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
  • A male or female between, and including, 15 and 18 months of age at the time of vaccination.
  • Written informed consent obtained from the parent or guardian of the subject.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Having participated in the primary vaccination study (CPMS N° 759346/007).

Exclusion criteria:

  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the vaccination, or planned use during the study period.
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to vaccination.
  • Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of vaccination.
  • Booster vaccination against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b (Hib) and/or meningococcal serogroups A, C or W disease, after the date of the study conclusion visit of the primary vaccination study (CPMS N° 759346/007).
  • History of diphtheria, tetanus, pertussis, hepatitis B, Hib and/or meningococcal serogroup A, C or W disease.
  • Known exposure to diphtheria, tetanus, pertussis, hepatitis B, Hib and/or meningococcal serogroup A, C or W disease.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • A family history of congenital or hereditary immunodeficiency.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccines administered in the study.
  • Major congenital defects or serious chronic illness.
  • History of any neurologic disorders or seizures including febrile seizures in infancy.
  • Acute disease at the time of enrolment.
  • Axillary temperature ≥ 37.5°C at the time of vaccination.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the vaccination or planned administration during the study period.
  • Anaphylactic reaction following the administration of vaccine in the primary vaccination study.
  • Known hypersensitivity to any component of the vaccine, or subjects having shown signs of hypersensitivity after previous administration of diphtheria, tetanus, pertussis, hepatitis B, Hib or meningococcal vaccines.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: AC primed Group
생물학적: Tritanrix™- HepB
One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
생물학적: Hiberix™
One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
생물학적: Mencevax™ ACW
One subcutaneous dose during the booster vaccination study in subjects aged 24 to 30 months
활성 비교기: AC unprimed Group
생물학적: Tritanrix™- HepB
One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
생물학적: Hiberix™
One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
생물학적: Mencevax™ ACW
One subcutaneous dose during the booster vaccination study in subjects aged 24 to 30 months

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Number of Subjects With Serum Bactericidal Assay Against N. Meningitidis Serogroups A, C Using Rabbit Complement (rSBA-MenA,C) Antibodies
기간: At one month post vaccination with Mencevax™ ACW vaccine (Month 25-31)
Pre-defined assay cut-off values for assessed titers were greater than or equal to (≥) 1:128.
At one month post vaccination with Mencevax™ ACW vaccine (Month 25-31)

2차 결과 측정

결과 측정
측정값 설명
기간
Number of Subjects With rSBA-MenA,C, W-135 Antibody Titers ≥ Predefined Cut-offs
기간: Prior to (Months 24-30) & one month after the administration of the Mencevax™ ACW vaccine (Months 25-31)
Antibody titer cut-offs were ≥ 1:8 and ≥ 1:128.
Prior to (Months 24-30) & one month after the administration of the Mencevax™ ACW vaccine (Months 25-31)
Anti-rSBA-MenA, C, W-135 Antibody Titers
기간: Prior to (Months 24-30) & one month after the administration of the Mencevax™ ACW vaccine (Months 25-31)
Antibody titers were expressed as geometric mean titers (GMTs).
Prior to (Months 24-30) & one month after the administration of the Mencevax™ ACW vaccine (Months 25-31)
Number of Subjects With Anti-polysaccharide A (Anti-PSA) and C (Anti-PSC) Antibody Concentrations Above Predefined Cut-off Values
기간: Prior to (Months 24-30) & one month after the administration of the Mencevax™ ACW vaccine (Months 25-31)
Antibody concentrations cut-off were ≥ 0.3 and ≥2 micrograms per millilitre (µg/mL).
Prior to (Months 24-30) & one month after the administration of the Mencevax™ ACW vaccine (Months 25-31)
Anti-PSA and Anti-PSC Antibody Concentrations
기간: Prior to (Months 24-30) & one month after the administration of the Mencevax™ ACW vaccine (Months 25-31
Antibody concentrations were expressed as Geometric Mean Concentrations (GMCs).
Prior to (Months 24-30) & one month after the administration of the Mencevax™ ACW vaccine (Months 25-31
Number of Subjects With Anti- Polysaccharide W (Anti-PSW) Antibody Concentrations ≥ Predefined Cut-off Values
기간: Prior to (Months 24-30) & one month after the administration of the Mencevax™ ACW vaccine (Months 25-31)
Antibody concentrations were ≥ 0.3 µg/mL.
Prior to (Months 24-30) & one month after the administration of the Mencevax™ ACW vaccine (Months 25-31)
Anti-PSW Antibody Concentrations
기간: Prior to (Months 24-30) & one month after the administration of the Mencevax™ ACW vaccine (Months 25-31)
Antibody concentrations were expressed as Geometric Mean Concentrations (GMCs).
Prior to (Months 24-30) & one month after the administration of the Mencevax™ ACW vaccine (Months 25-31)
Number of Subjects With Anti-hepatitis B (Anti-HBs) Antibody Concentrations ≥ Predefined Cut-off Values
기간: Prior to (Months 24-30) the administration of the Mencevax™ ACW vaccine
Antibody concentrations cut-off were ≥ 10 milli international units per milliliter (mIU/mL).
Prior to (Months 24-30) the administration of the Mencevax™ ACW vaccine
Anti-HBs Antibody Concentrations
기간: Prior to (Months 24-30) the administration of the Mencevax™ ACW vaccine
Antibody concentrations were expressed as Geometric Mean Concentrations (GMCs).
Prior to (Months 24-30) the administration of the Mencevax™ ACW vaccine
Number of Subjects With Vaccine Response for rSBA-Men A, C and W-135
기간: At one month after the administration of the Mencevax™ ACW vaccine (Months 25-31)
Vaccine response was defined as follows: for initially seronegative subjects (i.e. with rSBA titre < 1:8 pre-vaccination), rSBA titre ≥ 1:32 post-vaccination (seroconversion), and for initially seropositive subjects (i.e. with rSBA titre ≥ 1:8 pre-vaccination), at least a 4-fold increase in rSBA titre from pre to post-vaccination.
At one month after the administration of the Mencevax™ ACW vaccine (Months 25-31)
Number of Subjects With Fever
기간: During the 4-day (Days 0-3) after the administration of the Tritanrix™-HepB/Hiberix™ vaccine
Any Fever (measured rectally) = subjects with symptom, regardless of the intensity grade.
During the 4-day (Days 0-3) after the administration of the Tritanrix™-HepB/Hiberix™ vaccine
Number of Subjects With Solicited Local Symtoms
기간: During the 4-Day (Days 0-3) after the administration of the Mencevax™ ACW vaccine
Assessed solicited local symptoms were: pain, redness and swelling at the injection site. Any = subjects with symptom, regardless of the intensity grade.
During the 4-Day (Days 0-3) after the administration of the Mencevax™ ACW vaccine
Number of Subjects With Solicited General Symptoms
기간: During the 4-Day (Days 0-3) after the administration of the Mencevax™ ACW vaccine
Assessed solicited general symptoms were: drowsiness, fever, irritability and loss of appetite. Any = subjects with symptoms, regardless of intensity grade and casual relationship to study vaccination.
During the 4-Day (Days 0-3) after the administration of the Mencevax™ ACW vaccine
Number of Subjects With Unsolicited Adverse Events (AEs)
기간: During the 31-Day (Days 0-30) after the administration of the Mencevax™ ACW vaccine
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
During the 31-Day (Days 0-30) after the administration of the Mencevax™ ACW vaccine
Number of Subjects With Serious Adverse Events (SAEs)
기간: From Months 15-18 and up to Months 25-31 post vaccination
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
From Months 15-18 and up to Months 25-31 post vaccination

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

GlaxoSmithKline

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2006년 4월 19일

기본 완료 (실제)

2007년 5월 1일

연구 완료 (실제)

2007년 5월 17일

연구 등록 날짜

최초 제출

2006년 2월 3일

QC 기준을 충족하는 최초 제출

2006년 4월 20일

처음 게시됨 (추정)

2006년 4월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2018년 6월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2018년 4월 26일

마지막으로 확인됨

2017년 1월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • 104756

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

연구 데이터/문서

  1. 연구 프로토콜
    정보 식별자: 104756
    정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
  2. 데이터 세트 사양
    정보 식별자: 104756
    정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
  3. 통계 분석 계획
    정보 식별자: 104756
    정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
  4. 정보에 입각한 동의서
    정보 식별자: 104756
    정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
  5. 개별 참가자 데이터 세트
    정보 식별자: 104756
    정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
  6. 임상 연구 보고서
    정보 식별자: 104756
    정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다